Purple Dahlia is a modern hybrid whose precise origins remain undocumented, leaving its full genetic lineage and breeding history obscured. Current horticultural records identify the strain as a descendant of Screaming Eagle, though breeders have not publicly confirmed the complete cross or the development timeline. Due to this lack of documented provenance, the exact development process of this variety remains a subject of speculation, as no official breeder description exists to clarify its intended characteristics or ancestral heritage.

The chemical expression of Purple Dahlia is defined by a complex terpene profile dominated by myrcene, followed by caryophyllene, linalool, humulene, limonene, beta-pinene, and bisabolol. Due to the inherent variables in cultivation, these compounds are an estimated primary concentration that informs the plant's distinct aromatic nuances. It is a THC-dominant variety, with an estimated THC content of approximately 12.5% and a CBD content of roughly 0%. The plant reaches maturity following a 64-day flowering period, providing a high yield for cultivators who maintain a moderate level of environmental control in both indoor and outdoor growing spaces.

Consumers typically report feeling relaxed, happy, and uplifted after use, making Purple Dahlia a candidate for addressing stress, pain, and sleep difficulties. As a modern hybrid, it serves a functional role in therapeutic contexts where these specific effects are desired. There are currently no recorded offspring for this strain, meaning its genetic contribution to future breeding programs remains limited to its documented lineage of Screaming Eagle.